Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neuroscience and neurodegenerative diseases with a market capitalization of $17.45 billion, finds itself at a ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and ...

Shares of NASDAQ BIIB opened at $119.19 on Tuesday. The business has a 50-day moving average of $140.08 and a two-hundred day moving average of $156.76. The company has a debt-to-equity ratio of 0 ...

Shout! Studios has acquired distributor Gravitas Ventures under its strategy to build the library as it continues to acquire and distribute film and television through for its multi-platform ...

Shout! Studios has acquired Gravitas Ventures from Anthem Sports & Entertainment. Financial terms of the sale were not disclosed. Shout! Studios said that, by acquiring Gravitas Ventures ...

The acquisition gives Shout! access to Gravitas Ventures’ library of 3,300 scripted, non-scripted, and sports-related feature film, documentary, and TV titles, and it means that Shout!

The multi-platform media company backed by Oaktree Capital Management, has acquired Gravitas Ventures from Anthem Sports & Entertainment, Inc. According to the official release, the addition to Shout!

Shout! Studios, the multi-platform media company backed by Oaktree Capital Management, has acquired Gravitas Ventures from Anthem Sports & Entertainment, Inc. The deal was finalized over the ...

U.S. pharma imports hit $200 billion in 2024, a 10% tariff could cost the sector $20 billion. Vertex and Alnylam are seen as most resilient to tariff, tax and Medicaid risks. Markets are messy ...

Argus analyst Jasper Hellweg downgraded Biogen (BIIB) to Hold from Buy. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter ...